AptaBio Therapeutics Inc. (293780.KQ)
KRW 6500.0
(-3.56%)
KRW 6500.0
(-3.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 38.19 Billion KRW | 920.02% |
| 2022 | 3.74 Billion KRW | 15.36% |
| 2021 | 3.24 Billion KRW | -4.64% |
| 2020 | 3.4 Billion KRW | 51.33% |
| 2019 | 2.24 Billion KRW | 11.52% |
| 2018 | 2.01 Billion KRW | 341.49% |
| 2017 | 456.78 Million KRW | 6.82% |
| 2016 | 427.63 Million KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 38.19 Billion KRW | 17.99% |
| 2024 Q1 | 32.36 Billion KRW | -15.25% |
| 2023 Q3 | 36.88 Billion KRW | 761.84% |
| 2023 FY | 38.19 Billion KRW | 920.02% |
| 2023 Q4 | 38.19 Billion KRW | 3.53% |
| 2023 Q2 | 4.28 Billion KRW | 8.1% |
| 2023 Q1 | 3.95 Billion KRW | 5.76% |
| 2022 Q2 | 4.31 Billion KRW | 34.63% |
| 2022 Q1 | 3.2 Billion KRW | -1.25% |
| 2022 Q4 | 3.74 Billion KRW | 0.39% |
| 2022 Q3 | 3.72 Billion KRW | -13.57% |
| 2022 FY | 3.74 Billion KRW | 15.36% |
| 2021 Q1 | 3.74 Billion KRW | 9.94% |
| 2021 FY | 3.24 Billion KRW | -4.64% |
| 2021 Q4 | 3.24 Billion KRW | 9.73% |
| 2021 Q3 | 2.95 Billion KRW | -17.21% |
| 2021 Q2 | 3.57 Billion KRW | -4.52% |
| 2020 Q2 | 2.31 Billion KRW | -15.29% |
| 2020 FY | 3.4 Billion KRW | 51.33% |
| 2020 Q4 | 3.4 Billion KRW | 51.36% |
| 2020 Q3 | 2.24 Billion KRW | -2.66% |
| 2020 Q1 | 2.72 Billion KRW | 21.25% |
| 2019 Q2 | 2.19 Billion KRW | 0.0% |
| 2019 Q4 | 2.24 Billion KRW | -27.73% |
| 2019 Q3 | 3.11 Billion KRW | 41.66% |
| 2019 FY | 2.24 Billion KRW | 11.52% |
| 2018 Q4 | 2.01 Billion KRW | 0.0% |
| 2018 FY | 2.01 Billion KRW | 341.49% |
| 2017 FY | 456.78 Million KRW | 6.82% |
| 2016 FY | 427.63 Million KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 53.19 Billion KRW | 28.208% |
| CMG Pharmaceutical Co., Ltd. | 40.02 Billion KRW | 4.592% |
| Celltrion Pharm, Inc. | 264.97 Billion KRW | 85.587% |
| Huons Global Co., Ltd. | 407.28 Billion KRW | 90.623% |
| DongKook Pharmaceutical Co., Ltd. | 263.36 Billion KRW | 85.498% |
| Enzychem Lifesciences Corporation | 16.91 Billion KRW | -125.736% |
| Humedix Co., Ltd. | 21.91 Billion KRW | -74.276% |
| Boditech Med Inc. | 30.48 Billion KRW | -25.28% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | 43.69% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -328.218% |
| Huons Co., Ltd. | 206.87 Billion KRW | 81.539% |
| BNC Korea Co., Ltd. | 21.94 Billion KRW | -74.027% |